



Turning Data Into Insights - Securely and Intelligently

Your Queries and Content Secure and Safe

Comphas provides you with the capabilities - through online access to FDA and EMA data - to focus on opportunities empowering researchers to investigate, Boards to understand, and management to ask the right questions.

This approach enables smarter budget allocation on a day-to-day basis, supports data-driven arguments for pausing or extending projects, and creates a more transparent and accountable decision-making environment. For every Pharma or Biotech company, our tools foster a culture of critical thinking, helping to document complex decisions and turn challenges into opportunities - ultimately saving significant costs for your organization, trials, and network.

Every query within an organization reflects ideas, experiments, updates, and opportunities - all confidential by nature. Our platform is fully end-to-end encrypted, ensuring a secure space to communicate and collaborate on both opportunities and difficult decisions.

At Strategeens, our commitment is to bring **Change, Exploration, and Passion** to your organization - aligning teams and driving progress in a unified direction.

Business Intelligence

BI has several approaches, depending on the sector. It can be the cockpit to drive an organisation, or it can be the support of strategic thinking. In pharma and biotech it is strongly related to the process of aligning portfolios feeded by cooperation or ongoing successful trials.

As pharma and biotech became a multi-component and engineering market process, having a good cockpit and compass with Comphas is a great advantage to learn, explore and change.

From Bullseyes to an Integrated Toolset

Our initial SaaS Bullseyes ecosystem evolved into a powerful suite of interconnected modules:

- **Sharable Bullseyes and Timelines**
- **Access to FDA and EMA Clinical Trials**
- **PubMed Integration**
- **Social Listening:** Gain real-time understanding of patient sentiment worldwide of the products and treatments.
- **GeeForms:** Collect feedback and confidential data via **End-to-End Encrypted (E2EE)** forms for registrations, surveys, whistleblower programs, or clinical input.
 - Integration in the safe End to End encrypted environment
- **Early Birds:** Capture and securely transmit valuable symposium content (presentations, posters, or even informal findings)

Smart Data. Smarter Decisions.

Our **Clinical Trials UI** integrates directly with FDA and EMA APIs, allowing complex queries across over **700,000 studies** instantly visualized in dynamic dashboards and share it in a meeting or with your colleagues.

We are now building a **next-generation reporting platform** where all modules - Bullseyes, Timelines, PubMed, and more - connect through a single query.

This unified model reveals correlations between clinical trials, medical publications, and market indicators, enriching insights with internal data such as mechanisms of action or commercial potential.

The result: **data-driven decision-making** that's faster, clearer, and fully secure.


Collaboration Without Boundaries

A major strength of our solution is its **accessibility**. Insights can be shared with hundreds or even thousands of colleagues - without requiring additional software licenses (like Power BI).

All data is **centrally managed, securely stored**, and always available in the latest version.

CLINICAL TRIALS, BULLSEYES and TIMELINES

Clinical Trial Tool:



To set up a report should not be a process collecting data from internal or external resources, or copying data from our towards different spreadsheets or applications.

We can automate this process easily with some clicks from your computer or smartphone:

Step 1 – What Our SaaS Solution Delivers

Comphas provides **real-time access** to clinical trial data directly from the **FDA and EMA databases** - covering over **500,000 FDA** and **200,000 EMA** registered studies. As these databases continue to expand and evolve, they represent an increasingly **strategic asset** for research, competitive intelligence, and market planning.

However, public datasets often come with **incomplete or inconsistent information** - missing key fields such as mechanisms of action or classification details. Comphas turns this challenge into an opportunity: our platform intelligently enriches, harmonizes, and organizes the data, ensuring you can extract **precise, actionable insights**.

All analytical logic is **built into the platform** and can be **customized to client needs**. No more switching between tools or juggling spreadsheets. With Comphas, you can **generate strategic reports** directly from a **secure, end-to-end encrypted environment**, keeping your proprietary research and queries fully protected.

From a **single intuitive query**, you can instantly filter, analyze, and visualize data through **dynamic, interactive dashboards** - empowering faster, smarter decision-making.

Clinical Trials

Export

Save

Dashboards list

back to Apps

Hi, User

Logout

Search

Overview

ClinicalTrials.gov

Query

Search window

Search

Recruitment Status

☐ Active, not recruiting

☐ Completed

☐ Enrolling by invitation

☐ Not yet recruiting

☐ Recruiting

☐ Suspended

☐ Terminated

☐ Unknown status

☐ Withdrawn

☐ Withheld

Expanded Access Status

☐ Available

☐ No longer available

☐ Temporarily not available

☐ Approved for marketing

Study Phase

☐ Early phase 1

☐ Phase 1

☐ Phase 2

☐ Phase 3

☐ Phase 4

☐ Not applicable

Study Type

☐ Interventional

☐ Observational

☐ Expanded access

Study Results

☐ With results

☐ Without results

Funder Type

☐ FED

☐ Individuals

☐ Industry

☐ Network

☐ NIH

☐ Other (Organizations)

☐ Other (Government)

☐ Unknown

Date filters

Start Date

No Limit

From

To

Primary Completion Date

No Limit

From

To

Study First Post Date

No Limit

From

To

Results First Post Date

No Limit

From

To

Last Update Date

No Limit

From

To

Completion Date

No Limit

From

To

Study list

Visualize

Data

1 - 25 out of 556900 items

First

Prev

Next

Detach search data

COMPLETED

Source

Oral Immunotherapy for Peanut Allergy: Peanut Oral Immunotherapy (ProIT3)

Peanut allergy is known to cause severe anaphylactic reactions. The goal of this proposal is to produce a new treatment that would benefit subjects who have peanut allergy by lowering the risk of anaphylactic reactions (desensitization), and changing the peanut-specific immune response in subjects who have peanut allergy (tolerance).

Start date: 2009-04

Organization: University of North Carolina, Chapel Hill

Type: INTERVENTIONAL

Conditions: Peanut Hypersensitivity

Locations: United States, Chapel Hill

RECRUITING

Source

Pilot Randomized Controlled Trial Evaluating the Efficacy of Platelet-Rich Plasma (PRP) for Erectile Dysfunction

There is great interest in restorative therapies (platelet-rich plasma (PRP) injections, shockwave therapy and stem cell therapy) for ED given their non-invasive nature. However, data is still limited and requires further research prior to widespread adoption. Unfortunately, therapies such as PRP injections are being widely used without clinical evidence demonstrating its safety or effectiveness for the treatment of erectile dysfunction. 2-7 To date, there are no treatments that address the unde...

Start date: 2025-01-24 (ACTUAL)

Organization: University of Manitoba

Type: INTERVENTIONAL

Conditions: Erectile Dysfunction

Locations: Canada, Winnipeg

TERMINATED

Source

Randomized Phase II Study of Standard Chemotherapy With Docetaxel With or Without Bimrafusp Alfa in Patients With Advanced NSCLC After Progressing on a Combination of Anti-PD-1/PD-L1 Agents and Chemotherapy

This phase II trial studies how well docetaxel works with or without bimrafusp alfa in treating patients with non-small cell lung cancer that has spread to other places in the body (advanced). Chemotherapy drugs, such as docetaxel, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with bimrafusp alfa, may induce changes in body's immune system and may interfere with the abili...

Start date: 2020-10-23 (ACTUAL)

Organization: Mayo Clinic

Type: INTERVENTIONAL

Conditions: Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AZCC v8, Stage IIA Lung Cancer AZCC v8, Stage IIB Lung Cancer AZCC v8, Stage IIC Lung Cancer AZCC v8, Stage IV Lung Cancer AZCC v8, Stage IVA Lung Cancer AZCC v8, Stage IVB Lung Cancer AZCC v8

Locations: United States, Scottsdale, United States, Jacksonville, United States, Rochester

UNKNOWN

Source

A Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of a Fixed Dose Combination of Telmisartan and S-Amlodipine (TELMINUVO TAB) Versus S-Amlodipine Monotherapy in Patients With Stage 2 Hypertension

The aim of present study is to evaluate the efficacy and safety of two dose combination of Telmisartan/S-Amlodipine (80/2.5mg and 80/5mg) compared with S-Amlodipine monotherapy (2.5mg and 5mg) in patients with Stage 2 hypertension.

Start date: 2024-01

Organization: Chong Run Dang Pharmaceutical

Type: INTERVENTIONAL

Conditions: Hypertension

Locations: South Korea, Seoul

NOT_YET_RECRUITING

Source

Strategy-based Cognitive Rehabilitation with Integrated Fatigue Management for Patients with Paediatric Brain Tumour (PBT): an Acceptability and Feasibility Study of the Fatigue, Learning and Memory Enrichment (FLaME) Intervention

Medical treatments have improved survival rates for children with brain tumours. However, most children experience long-term difficulties with 'cognition' (thinking skills such as memory and paying attention) and cognitive fatigue (excessive mental tiredness) after treatment. Thinking difficulties and fatigue can affect a child's ability to learn, and their social and emotional wellbeing. National guidance recommends treatment called 'cognitive rehabilitation' which teaches skills to improve or...

Start date: 2025-05-10 (ESTIMATED)

Organization: Great Ormond Street Hospital for Children NHS Foundation Trust

Type: INTERVENTIONAL

Conditions: Childhood Brain Tumour, Childhood Brain Tumors, Pediatric Brain Neoplasms, Pediatric Brain Tumor

Locations: United Kingdom, London

COMPLETED

Source

Neutrophil Function During Combination Therapy With Protease Inhibitors in Chronic Hepatitis C

The aim of this study is to characterize neutrophil function in patients undergoing chronic hepatitis C triple therapy with protease inhibitors in comparison to dual therapy with peginterferon and ribavirin and with interferon free treatment regimen to thereby elucidate the possible mechanisms of protease-inhibitor associated infections.

Start date: 2014-11-01 (ACTUAL)

Organization: Medical University of Graz

Type: OBSERVATIONAL

Conditions: Chronic Hepatitis C

Locations: Austria, Gste

COMPLETED

Source

Exercise Coupled to Self Drainage in Pediatric Cystic Fibrosis Patients: an Open Label Cross Over Randomised Clinical Trial

In the current study, we designed a cross-over, open label, randomized controlled clinical trial that aim to investigate the superiority of physical exercise coupled with self drainage to a chest physiotherapy in stable cystic fibrosis children. We hypothesized that CF children undergoing physical exercise coupled to self drainage will increase the amount of expectorate secretions compared to conventional CP course, while being more satisfied and without worsening their pulmonary function status.

Start date: 2006-03

Organization: Hopital Hopital Civil de Lyon

Type: INTERVENTIONAL

Conditions: Cystic Fibrosis

COMPLETED

Source

The Role of Vitamin D in Female Reproductive Tract Immunity

The purpose of this study is to assess the impact of approximately 8 weeks of Vitamin D (VID) and calcium supplementation, using daily versus weekly supplementation regimens, on female reproductive tract immunity.

Start date: 2014-08

Organization: CONRAD

Type: INTERVENTIONAL

Conditions: Vitamin D Deficiency

Locations: United States, Norfolk

COMPLETED

Source

Incentive-based Smoking Cessation for Methadone Patients

The prevalence of cigarette smoking among patients receiving opioid agonist treatment, such as methadone or buprenorphine maintenance, is more than three-fold that of the general population and is associated with increased morbidity and mortality. The overarching goal of this project is to systematically develop a voucher-based contingency management (CM) intervention for promoting initial and longer-term abstinence from cigarette smoking in patients receiving methadone or buprenorphine treatment.

Start date: 2007-08

Organization: University of Vermont Medical Center

Type: INTERVENTIONAL

Conditions: Cigarette Smoking Among Patients Currently Receiving Methadone or Buprenorphine Treatment for Opioid Dependence

Locations: United States, Burlington

Figure: Direct Dashboard View on a EMA or FDA query (1)

With **powerful filtering capabilities**, users can easily refine their searches across multiple dimensions - including **study phase, therapeutic area, geographic region, sponsor, status, and more**. Whether you're exploring global clinical trial landscapes or drilling down into a **specific market or region**, Comphas gives you **full control and flexibility** over your data exploration.


Interactive filters enable you to uncover **hidden patterns, emerging trends, and competitive movements** in just a few clicks. You can quickly compare markets, assess development pipelines, and identify **untapped opportunities** - all from one centralized, intuitive platform.



Figure: Direct Dashboard View on a EMA or FDA query (2)

All kinds of **graphics and visualizations** can be fully customized to create your own **reporting templates**. From heat maps and bar charts to trend lines and comparative dashboards, Comphas lets you design **clear, impactful visuals** that translate complex data into **strategic insights**.

Save your preferred layouts and reuse them for future analyses, ensuring **consistency and efficiency** across teams and projects. With **drag-and-drop configuration** and **instant rendering**, you can turn any query into a presentation-ready report - perfectly aligned with your organization's branding and analytical standards.



The screenshot displays the Comphas Clinical Trials dashboard. The top navigation bar includes a search icon, the text 'Clinical Trials', and buttons for 'Export', 'Save', 'Dashboard list', 'back to Apps', 'Hi, User', and 'Logout'. Below the navigation bar, the dashboard is divided into three main sections: 'Search', 'Overview', and a table view. The 'Search' section on the left contains a search bar with 'ClinicalTrials.gov' and a 'Search window' button. The 'Overview' section on the right contains a 'Query' input field and a 'Search' button. The table view displays a list of clinical trials with columns for NCTID, Title, Organization, Lead Sponsor Name, Collaborator Names, Start Date, and Completion. The table is filtered by 'Recruitment Status' (Active, not recruiting; Completed; Enrolling by invitation; Not yet recruiting; Recruiting; Suspended; Terminated; Unknown status; Withdrawn; Withheld) and 'Expanded Access Status' (Available; No longer available; Temporarily not available; Approved for marketing). The table also has a 'Study Phase' filter. The table shows 1-679 out of 679 items. The table is sorted by 'NCTID' in ascending order. The table contains 22 rows of data. The first row is NCT0570597, titled 'Insert column left', with Organization 'Terumo Europe N.V.', Lead Sponsor Name 'Terumo Europe N.V.', Collaborator Names, Start Date '2023-04-25', and Completion '2027-04-29'. The second row is NCT0617354, titled 'Insert column right', with Organization 'Xencor, Inc.', Lead Sponsor Name 'Xencor, Inc.', Collaborator Names, Start Date '2023-12-27', and Completion '2027-10'. The third row is NCT0157203, titled 'Remove column', with Organization 'Hoffmann-La Roche', Lead Sponsor Name 'Hoffmann-La Roche', Collaborator Names, Start Date '2012-06-01', and Completion '2019-09-20'. The fourth row is NCT0240934, titled 'Clear column', with Organization 'Bristol-Myers Squibb', Lead Sponsor Name 'Bristol-Myers Squibb', Collaborator Names 'PPD Development, LP', Start Date '2015-04-29', and Completion '2021-08-27'. The fifth row is NCT0077338, titled 'Read only', with Organization 'Hoffmann-La Roche', Lead Sponsor Name 'Hoffmann-La Roche', Collaborator Names, Start Date '2008-11', and Completion '2010-02'. The sixth row is NCT0365672, titled 'Alignment', with Organization 'Bristol-Myers Squibb', Lead Sponsor Name 'Bristol-Myers Squibb', Collaborator Names, Start Date '2018-10-29', and Completion '2024-09-12'. The seventh row is NCT0432374, titled 'Filter by condition', with Organization 'Gilead Sciences', Lead Sponsor Name 'Gilead Sciences', Collaborator Names, Start Date '2023-12-31', and Completion '2028-08-18'. The eighth row is NCT0607981, titled 'None', with Organization 'Merck Sharp & Dohme LLC', Lead Sponsor Name 'Merck Sharp & Dohme LLC', Collaborator Names, Start Date '2023-12-31', and Completion '2028-08-18'. The ninth row is NCT0322554, titled 'Filter by value', with Organization 'Population Health Research Ins', Lead Sponsor Name 'Population Health Research Ins', Collaborator Names 'Canadian Institutes of Health Research', Start Date '2002-01-01', and Completion '2030-12-31'. The tenth row is NCT0451396, titled 'Search', with Organization 'Hoffmann-La Roche', Lead Sponsor Name 'Hoffmann-La Roche', Collaborator Names, Start Date '2020-08-24', and Completion '2025-07-31'. The eleventh row is NCT0404047, titled 'Select all Clear', with Organization 'Hoffmann-La Roche', Lead Sponsor Name 'Hoffmann-La Roche', Collaborator Names, Start Date '2006-08', and Completion '2008-02'. The twelfth row is NCT0417322, titled 'Safety of First-line Treatment With Avastin in Combi', with Organization 'Pfizer', Lead Sponsor Name 'Pfizer', Collaborator Names 'Arena is a wholly owned subsidiary of F', Start Date '2020-01-06', and Completion '2025-06-09'. The thirteenth row is NCT0450378, titled 'Double-Blind, Parallel-Group Study to Assess the Ef', with Organization 'Amgen', Lead Sponsor Name 'Amgen', Collaborator Names, Start Date '2020-06-04', and Completion '2026-02-25'. The fourteenth row is NCT00002823, titled 'mized, Open Label, Active-controlled, Study of AM', with Organization 'Maria Skłodowska-Curie Nator', Lead Sponsor Name 'Maria Skłodowska-Curie Nator', Collaborator Names 'Institute of Tuberculosis and Lung Dise', Start Date '2003-04', and Completion '2007-09'. The fifteenth row is NCT0111266, titled 'Quality of Life and Cardiopulmonary Morbidity After', with Organization 'Bristol-Myers Squibb', Lead Sponsor Name 'Bristol-Myers Squibb', Collaborator Names, Start Date '2024-10-07', and Completion '2032-08-04'. The sixteenth row is NCT0656138, titled 'Open-label Study of Nivolumab + Relatlimab Fixed-dos', with Organization 'European Organisation for Resi', Lead Sponsor Name 'European Organisation for Resi', Collaborator Names 'UNICANCER', Start Date '2022-12-29', and Completion '2027-11-01'. The seventeenth row is NCT0479025, titled 'on or Active MAgnetic Resonance Imaging Survei', with Organization 'AstraZeneca', Lead Sponsor Name 'AstraZeneca', Collaborator Names, Start Date '2015-10-22', and Completion '2021-07-07'. The eighteenth row is NCT0568729, titled 'y-label, Multicentre, Global Study of Datopotamab', with Organization 'Bristol-Myers Squibb', Lead Sponsor Name 'Bristol-Myers Squibb', Collaborator Names 'Pfizer', Start Date '2017-12-14', and Completion '2022-09-07'. The nineteenth row is NCT0236968, titled 'Label, Multi-center Study of the Safety and Efficacy', with Organization 'Merck Sharp & Dohme LLC', Lead Sponsor Name 'Merck Sharp & Dohme LLC', Collaborator Names 'Actelion', Start Date '2017-07-05', and Completion '2024-01-16'. The twentieth row is NCT03302234, titled 'Multicenter, Non-comparative Extension of Study AC-0588301, to Investigate th', with Organization 'Bayer', Lead Sponsor Name 'Bayer', Collaborator Names, Start Date '2024-08-28', and Completion '2029-04-26'. The twenty-first row is NCT03232073, titled 'A Phase 3 Open-label, Randomized, Active-controlled, Multicenter Trial to Evalu', with Organization 'Pfizer', Lead Sponsor Name 'Pfizer', Collaborator Names 'Medivation, Inc.', Start Date '2013-10-14', and Completion '2021-03-05'. The twenty-second row is NCT06452277, titled 'A Phase 3, OPEN-LABEL, RANDOMIZED PARALLEL-2-ARM, MULTI-CENTER STUD', with Organization 'Pfizer', Lead Sponsor Name 'Pfizer', Collaborator Names, Start Date, and Completion.

Figure: Direct Dashboard View on a EMA or FDA query (3)

Add **additional visualizations** on any available public data field - with **thousands of possible combinations**, your report can expand as far as your analysis requires. Whether you're mapping trial density by region, comparing study phases, or tracking sponsor activity over time, Comphas empowers you to **build insights without limits**.

At any point in your workflow, you can **download, export, or securely share** your findings. Reports can be delivered in multiple formats or shared directly through the **encrypted Comphas environment**, ensuring that **your data and insights remain protected** while still enabling **seamless collaboration** across teams or partners

A major advantage of Comphas is the ability to **share reports seamlessly** with colleagues - allowing them to explore, filter, and interact with the data **without additional licensing constraints**.

All collaboration takes place within **secure, encrypted “Rooms”**, where authorized team members can **discuss findings, add insights, and exchange ideas** in a protected environment. This ensures that strategic discussions remain **confidential** while maintaining full traceability of contributions and updates.

Step 2 – your own report in minutes

Once your analysis and feedback are complete, Comphas automatically compiles your results into a **dynamic table view** featuring familiar **spreadsheet-like functionalities**.

You can **add, rearrange, and search columns**, perform **custom calculations**, and enrich your dataset with additional inputs such as **Mechanism of Action, budget estimates, market relevance, CRM data, or internal comments**.

Dashboards can be instantly **updated with new information**, keeping your insights current and decision-ready.

All generated data and reports can be **seamlessly integrated into advanced visualization tools** such as **Bullseyes** or **Timelines** for deeper simulation, trend analysis, and collaborative review - enabling your teams to move from **data exploration to strategy execution** effortlessly.

Clinical Trials

Export

Save

Dashboard list

back to Apps

Hi, User

Logout

Search

Overview

ClinicalTrials.gov

Query

Search window

Search

Recruitment Status

☐ Active, not recruiting

☐ Completed

☐ Enrolling by invitation

☐ Not yet recruiting

☐ Recruiting

☐ Suspended

☐ Terminated

☐ Unknown status

☐ Withdrawn

☐ Withheld

Expanded Access Status

☐ Available

☐ No longer available

☐ Temporarily not available

☐ Approved for marketing

Study Phase

☐ Early phase 1

☐ Phase 1

☐ Phase 2

☐ Phase 3

☐ Phase 4

☐ Not applicable

Study Type

☐ Interventional

☐ Observational

☐ Expanded access

Study Results

☐ With results

☐ Without results

Funder Type

☐ FED

☐ Individuals

☐ Industry

☐ Network

☐ NIH

☐ Other (Organizations)

☐ Other (Government)

☐ Unknown

Date filters

Start Date

No Limit

From

To

Primary Completion Date

No Limit

From

To

Study First Post Date

No Limit

From

To

Results First Post Date

No Limit

From

To

Last Update Date

No Limit

From

To

Completion Date

No Limit

From

To

Study list

Visualize

Data

1 - 25 out of 556900 items

First

Prev

Next

Detach search data

COMPLETED

Source

Oral Immunotherapy for Peanut Allergy: Peanut Oral Immunotherapy (ProIT3)

Peanut allergy is known to cause severe anaphylactic reactions. The goal of this proposal is to produce a new treatment that would benefit subjects who have peanut allergy by lowering the risk of anaphylactic reactions (desensitization), and changing the peanut-specific immune response in subjects who have peanut allergy (tolerance).

Start date: 2009-04

Organization: University of North Carolina, Chapel Hill

Type: INTERVENTIONAL

Conditions: Peanut Hypersensitivity

Locations: United States, Chapel Hill

RECRUITING

Source

Pilot Randomized Controlled Trial Evaluating the Efficacy of Platelet-Rich Plasma (PRP) for Erectile Dysfunction

There is great interest in restorative therapies (platelet-rich plasma (PRP) injections, shockwave therapy and stem cell therapy) for ED given their non-invasive nature. However, data is still limited and requires further research prior to widespread adoption. Unfortunately, therapies such as PRP injections are being widely used without clinical evidence demonstrating its safety or effectiveness for the treatment of erectile dysfunction. 2-7 To date, there are no treatments that address the unde...

Start date: 2025-01-24 (ACTUAL)

Organization: University of Manitoba

Type: INTERVENTIONAL

Conditions: Erectile Dysfunction

Locations: Canada, Winnipeg

TERMINATED

Source

Randomized Phase II Study of Standard Chemotherapy With Docetaxel With or Without Bimrafusp Alfa in Patients With Advanced NSCLC After Progressing on a Combination of Anti-PD-1/PD-L1 Agents and Chemotherapy

This phase II trial studies how well docetaxel works with or without bimrafusp alfa in treating patients with non-small cell lung cancer that has spread to other places in the body (advanced). Chemotherapy drugs, such as docetaxel, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with bimrafusp alfa, may induce changes in body's immune system and may interfere with the abili...

Start date: 2020-10-23 (ACTUAL)

Organization: Mayo Clinic

Type: INTERVENTIONAL

Conditions: Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AZCC v8, Stage IIA Lung Cancer AZCC v8, Stage IIB Lung Cancer AZCC v8, Stage IIC Lung Cancer AZCC v8, Stage IV Lung Cancer AZCC v8, Stage IVA Lung Cancer AZCC v8, Stage IVB Lung Cancer AZCC v8

Locations: United States, Scottsdale, United States, Jacksonville, United States, Rochester

UNKNOWN

Source

A Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of a Fixed Dose Combination of Telmisartan and S-Amlodipine (TELMINUVO TAB) Versus S-Amlodipine Monotherapy in Patients With Stage 2 Hypertension

The aim of present study is to evaluate the efficacy and safety of two dose combination of Telmisartan/S-Amlodipine (80/2.5mg and 80/5mg) compared with S-Amlodipine monotherapy (2.5mg and 5mg) in patients with Stage 2 hypertension.

Start date: 2024-01

Organization: Chong Run Dang Pharmaceutical

Type: INTERVENTIONAL

Conditions: Hypertension

Locations: South Korea, Seoul

NOT_YET_RECRUITING

Source

Strategy-based Cognitive Rehabilitation with Integrated Fatigue Management for Patients with Paediatric Brain Tumour (PBT): an Acceptability and Feasibility Study of the Fatigue, Learning and Memory Enrichment (FLaME) Intervention

Medical treatments have improved survival rates for children with brain tumours. However, most children experience long-term difficulties with 'cognition' (thinking skills such as memory and paying attention) and cognitive fatigue (excessive mental tiredness) after treatment. Thinking difficulties and fatigue can affect a child's ability to learn, and their social and emotional wellbeing. National guidance recommends treatment called 'cognitive rehabilitation' which teaches skills to improve or...

Start date: 2025-05-10 (ESTIMATED)

Organization: Great Ormond Street Hospital for Children NHS Foundation Trust

Type: INTERVENTIONAL

Conditions: Childhood Brain Tumour, Childhood Brain Tumors, Pediatric Brain Neoplasms, Pediatric Brain Tumor

Locations: United Kingdom, London

COMPLETED

Source

Neutrophil Function During Combination Therapy With Protease Inhibitors in Chronic Hepatitis C

The aim of this study is to characterize neutrophil function in patients undergoing chronic hepatitis C triple therapy with protease inhibitors in comparison to dual therapy with peginterferon and ribavirin and with interferon free treatment regimen to thereby elucidate the possible mechanisms of protease-inhibitor associated infections.

Start date: 2014-11-01 (ACTUAL)

Organization: Medical University of Graz

Type: OBSERVATIONAL

Conditions: Chronic Hepatitis C

Locations: Austria, Grit

COMPLETED

Source

Exercise Coupled to Self Drainage in Pediatric Cystic Fibrosis Patients: an Open Label Cross Over Randomised Clinical Trial

In the current study, we designed a cross-over, open label, randomized controlled clinical trial that aim to investigate the superiority of physical exercise coupled with self drainage to a chest physiotherapy in stable cystic fibrosis children. We hypothesized that CF children undergoing physical exercise coupled to self drainage will increase the amount of expectorate secretions compared to conventional CP course, while being more satisfied and without worsening their pulmonary function status.

Start date: 2006-03

Organization: Hopital Civil de Lyon

Type: INTERVENTIONAL

Conditions: Cystic Fibrosis

COMPLETED

Source

The Role of Vitamin D in Female Reproductive Tract Immunity

The purpose of this study is to assess the impact of approximately 8 weeks of Vitamin D (VID) and calcium supplementation, using daily versus weekly supplementation regimens, on female reproductive tract immunity.

Start date: 2014-08

Organization: CONRAD

Type: INTERVENTIONAL

Conditions: Vitamin D Deficiency

Locations: United States, Norfolk

COMPLETED

Source

Incentive-based Smoking Cessation for Methadone Patients

The prevalence of cigarette smoking among patients receiving opioid agonist treatment, such as methadone or buprenorphine maintenance, is more than three-fold that of the general population and is associated with increased morbidity and mortality. The overarching goal of this project is to systematically develop a voucher-based contingency management (CM) intervention for promoting initial and longer-term abstinence from cigarette smoking in patients receiving methadone or buprenorphine treatment.

Start date: 2007-08

Organization: University of Vermont Medical Center

Type: INTERVENTIONAL

Conditions: Cigarette Smoking Among Patients Currently Receiving Methadone or Buprenorphine Treatment for Opioid Dependence

Locations: United States, Burlington

Figure: Detach the data from EMA or FDA query

By detaching the data, a table view (“spreadsheet”) is generated. Additional columns can be created, and logic can be built in to automatically combine elements from different columns into new ones.

These extra columns can be configured within dashboard views, exported to Excel, or integrated into tools such as Bullseyes.

By combining the rich dataset from over 700,000 online clinical trials with fields from external databases or internal data-such as forecasts, budgets, and marketing information-new insights can be uncovered to guide strategic decisions and budget planning.

NCTId	Title	Organization	Lead Sponsor Name	Collaborator Names	Start Date	Completion Date	Status	
1	NCT05705973	A Post-Market Clinical Follow-up	Terumo Europe N.V.	Terumo Europe N.V.	2023-04-25	2027-04-29	ACTIVE_NOT_RECR	The NAGOMI C
2	NCT06173505	A Phase 1b/2. Open-label, Randc	Xencor, Inc.	Xencor, Inc.	2023-12-27	2027-10	RECRUITING	The purpose of
3	NCT01572038	A Multicenter, Open-Label, Singl	Hoffmann-La Roche	Hoffmann-La Roche	2012-06-01	2019-09-20	COMPLETED	This multicente
4	NCT02409368	An Open-Label, Multicenter Clini	Bristol-Myers Squibb	Bristol-Myers Squibb	2015-04-29	2021-08-27	COMPLETED	The purpose of
5	NCT00773383	An Open-label Study to Determi	Hoffmann-La Roche	Hoffmann-La Roche	2008-11	2010-02	TERMINATED	This single arm
6	NCT03656718	Phase I/II Pharmacokinetic Multi	Bristol-Myers Squibb	Bristol-Myers Squibb	2018-10-29	2024-09-12	COMPLETED	The purpose of
7	NCT04323761	Expanded Access Treatment Prot	Gilead Sciences	Gilead Sciences			APPROVED_FOR_M	The primary ob
8	NCT06079879	A Phase 3. Randomized, Open-la	Merck Sharp & Dohme LLC	Merck Sharp & Dohme LLC	2023-12-31	2028-08-18	RECRUITING	This is a study v
9	NCT03225586	Prospective Urban Rural Epidemi	Population Health Research Ins	Population Health Research Ins	2002-01-01	2030-12-31	RECRUITING	To examine the
10	NCT04513925	A Phase III. Open-Label, Random	Hoffmann-La Roche	Hoffmann-La Roche	2020-08-24	2025-07-31	COMPLETED	The purpose of
11	NCT00404703	An Open Label Study of the Safe	Hoffmann-La Roche	Hoffmann-La Roche	2006-08	2008-02	TERMINATED	This single arm
12	NCT04173273	A Multicenter, Randomized, Dou	Pfizer	Pfizer	2020-01-06	2025-06-09	TERMINATED	This is a Phase
13	NCT04303780	A Phase 3 Multicenter, Randomiz	Amgen	Arena is a wholly owned subsidiary of F	2020-06-04	2026-02-25	ACTIVE_NOT_RECR	A Phase 3 Stud
14	NCT01112631	Prospective Comparison of Quali	Maria Sklodowska-Curie Natio	Maria Sklodowska-Curie Natio	2003-04	2007-09	COMPLETED	The patients fr
15	NCT06561386	A Phase 3. Randomized, Open-la	Bristol-Myers Squibb	Bristol-Myers Squibb	2024-10-07	2032-08-04	RECRUITING	The purpose of
16	NCT04790253	Pflogylactic Cerebral Irradiation	European Organisation for Res	European Organisation for Res	2022-10-27	2028-04	RECRUITING	In this phase III
17	NCT05687266	A Phase III. Randomised, Open-l	AstraZeneca	AstraZeneca	2022-12-29	2027-11-01	ACTIVE_NOT_RECR	This is a Phase
18	NCT02369653	A Phase III Randomized, Open La	Bristol-Myers Squibb	Bristol-Myers Squibb	2015-10-22	2021-07-07	COMPLETED	The purpose of
19	NCT03302234	A Phase 3. Randomized, Double-	Merck Sharp & Dohme LLC	Merck Sharp & Dohme LLC	2017-12-14	2022-09-07	COMPLETED	The purpose of
20	NCT03232073	Multicenter, Non-comparative Ex	Actelion		2017-07-05	2024-01-16	COMPLETED	The study AC-C
21	NCT04522277	A Phase 3 Open-label, Randomiz	Bayer		2024-08-28	2029-04-26	RECRUITING	Researchers are
22	NCT01945775	A PHASE 3. OPEN-LABEL, RANDC	Pfizer	Medivation, Inc.	2013-10-14	2021-03-05	COMPLETED	The purpose of v

Figure: Insert extra data in the Dashboard View after a EMA or FDA query

Bullseyes:




Figure: Bullseyes view on your query or dashboard results on a EMA or FDA query

A **bullseye graphic** is a powerful visual tool used to **prioritize, compare, and communicate strategic focus areas** across research, development, and commercialization.

The main goal in pharma to use it is to get overviews of ongoing Clinical Trials, but the tool can also be used for other purposes as the circles (typically phases) can be replaced with other valuables (years, budgets,...).

1. Portfolio Prioritization

- **Purpose:** To show which drugs, assets, or programs are most strategically important.

- **How it's used:**

- The center (bullseye) shows **high-priority or high-potential** programs.
- Outer rings show **lower-priority, longer-term, or less aligned** projects.
Example: Visualizing which clinical candidates are closest to market readiness or best fit company objectives.

2. Clinical Trial Targeting

- **Purpose:** To identify **key indications, trial sites, or patient populations.**

- **How it's used:**

- The bullseye might represent **ideal patient populations,**
- Outer rings represent **less optimal or exploratory targets.**
- *Example:* Mapping which trial sites are most aligned with recruitment goals or data quality standards.

3. Market Opportunity Assessment

- **Purpose:** To visualize **commercial attractiveness** or **market fit.**

- **How it's used:**

- The center shows **high-value markets or customer segments.**
- Outer rings show **secondary opportunities.**
Example: Prioritizing therapeutic areas or geographies for launch planning.

4. Brand and Competitive Strategy

- **Purpose:** To **position brands** or **competitors** based on performance, differentiation, or alignment with strategic drivers.

Example: Displaying how different products align with unmet needs, innovation focus, or payer interest.

5. Data Integration and Insight Visualization

- **Purpose:** To bring together **internal data (e.g., forecasts, budgets)** and **external data (e.g., 700k clinical trials, market trends)** into one visual that reveals **where to focus efforts**.

Example: Highlighting where investment or marketing focus should concentrate for maximum ROI.

A bullseye graphic in pharma is used to visualize what deserves the most attention-whether it's molecules, markets, trials, or strategies-by showing how close each element is to the core business or scientific goal.

A Bullseye can easily be shared within an organisation.

Timelines:

A **timeline graphic** is a powerful visual tool, helping to communicate complex processes, research milestones, and project progress in a clear, chronological format.

With our Timeline tool you could better visualise:

1. Drug Development & R&D

- **Clinical trial phases:** Visualizing progress from **preclinical research search (clinical trial tool)** → **Phase I** → **Phase II** → **Phase III** → **FDA/EMA approval**.
- **Molecule discovery milestones:** Showing key experiments, discovery dates, or go/no-go decisions.
- **Research project planning:** Outlining timelines for formulation, toxicology studies, and analytical development.

2. Regulatory & Compliance

- **Submission tracking:** Mapping timelines for **IND, NDA, ANDA, MAA**, or **BLA** submissions and reviews.
- **Audit preparation:** Showing inspection and compliance audit schedules.
- **Post-approval commitments:** Tracking pharmacovigilance or post-marketing study deadlines.

3. Manufacturing & Supply Chain

- **Scale-up and tech transfer:** Showing milestones from **lab scale** → **pilot** → **commercial production**.
- **Facility qualification:** Timelines for equipment installation, validation (IQ/OQ/PQ), and readiness.
- **Supply chain readiness:** Visualizing API sourcing, batch production, packaging, and distribution phases.

4. Product Launch & Marketing

- **Launch roadmap:** Showing pre-launch, launch, and post-launch activities (e.g., HCP education, regulatory approval, market rollout).
- **Lifecycle management:** Mapping product improvements, new indications, or reformulations over time.
- **Competitor tracking:** Comparing your product timeline against competitors' development stages.

5. Medical Affairs & Communication

- **Publication plan:** Timeline of abstracts, conference presentations, and journal submissions.
- **Patient engagement programs:** Visualizing stages of education, recruitment, and long-term follow-up.
- **Medical education campaigns:** Showing rollout of training materials or advisory board sessions.

6. Corporate Strategy

- **Portfolio overview:** Displaying multiple projects and their development phases in parallel.
- **M&A or licensing milestones:** Visualizing deal closures, integration phases, and co-development schedules.
- **Strategic initiatives:** Tracking sustainability goals, digital transformation, or quality improvement initiatives.




Figure: Timeline view Template 2




Figure: Timeline View template 3 on FDA query




Figure: Timeline extension on Template 2

Safe in the Geens.com Infrastructure

All our tools run within the **Geens.com secure infrastructure**, fully **End-to-End Encrypted** and deployed in **custom White Label environments**.

That means large organizations retain **full control. Nobody but you** can access your queries or discussions.

This model ensures:

- **Confidential collaboration:** Management can discuss and share sensitive information securely.
- **Data sovereignty:** Organizations decide what to retain, archive, or permanently delete.
- **Strategic empowerment:** Leadership gains full ownership of internal communication and decision flows, and asks the right questions.

And there are some positive site effects:...

Choosing our platform means more than adopting new tools - it's a catalyst for organizational change:

- Empower teams with autonomy and trust (Micro Organisations) avoiding overhead costs
- Encourage initiative, engagement, and innovation
- Replace rigid workflows with flexible, data-driven collaboration
- Enable **cross-company synergy** and **shared investment benefits**
- Create **secure spaces** for acquisitions, strategic discussions, and innovation projects.

HEALTH

COMPANY FILES

PERSONAL FILES

SHARED FILES

TRASH BIN

TIMESTAMPS

ROOMS

SERVICES

TEAM

SETTINGS

Health

Rooms

Room search

+ Add room

Meeting with ...

0 New Messages

0 Tasks

Room members

Den

0 New Messages

0 Tasks

Room members

×

↓

Drag and drop an image

Max file size: 20MB

or

Browse

Preview:

Team

Team > Edit Owner  jaakGeens#hea... +

Clients > Edit +

Add Users

Settings

Task List ☐

Chat ☒

Sub-Tasks ☒

Save

BALANCE: 0 GEE

1.2 TB OF 10 TB

jaakGeens#...